17 reviews for 5th Annual Update in Neuro-Oncology 2025

1. Dr. Natalie Brooks

   Rated 4 out of 5

   This course provides a broad, updated, and clinically relevant review of neuro-oncology. I found the pediatric tumor day especially valuable, since it...More

   This course provides a broad, updated, and clinically relevant review of neuro-oncology. I found the pediatric tumor day especially valuable, since it covers many tumor types that are difficult to review efficiently elsewhere. The adult neuro-oncology lectures are also strong, particularly the discussions of glioma classification, imaging, surgery, radiation, and experimental therapies. The final day on neurological complications of cancer adds practical value for clinicians who manage complex cancer patients. The content is dense but well structured, and the recorded access makes it easier to review challenging sections more than once.

   Helpful? 0 0
   Dr. Kevin O’Donnell

   Rated 4 out of 5

   I appreciated how practical this course felt despite covering advanced academic material. The sessions on standard and novel treatment approaches were...More

   I appreciated how practical this course felt despite covering advanced academic material. The sessions on standard and novel treatment approaches were particularly helpful, and the tumor board discussions made the learning feel closer to real clinical decision-making. The coverage of immunotherapy-related neurological complications is important because these issues are becoming more frequent in oncology practice. The course also gives useful attention to survivorship and long-term treatment effects. It is not a light overview, and some topics require prior knowledge, but it is a valuable course for clinicians who want a detailed update.

   Helpful? 0 0
   Dr. Sophia Martinez

   Rated 4 out of 5

   This neuro-oncology update is highly educational and well organized. The three-day structure makes sense, and each day has a clear theme that helps th...More

   This neuro-oncology update is highly educational and well organized. The three-day structure makes sense, and each day has a clear theme that helps the learner follow the progression of topics. I liked that the course includes both tumor-specific management and broader neurological complications of cancer. The faculty presentations feel authoritative, especially in molecular pathology, radiology, and experimental treatment areas. The course may be too advanced for someone without a medical background, but for clinicians and trainees it offers a strong, current, and practical review of the field.

   Helpful? 0 0
   Dr. Robert Hayes

   Rated 5 out of 5

   The best aspect of this course is the way it connects scientific advances with clinical management. Instead of treating imaging, pathology, surgery, r...More

   The best aspect of this course is the way it connects scientific advances with clinical management. Instead of treating imaging, pathology, surgery, radiation, and medical oncology as separate topics, the course makes it clear how they influence each other in CNS tumor care. I found the lectures on brain metastases and leptomeningeal disease very useful, especially because these are common and challenging problems in cancer patients. The pediatric content is also strong. I gave four stars because the material is dense, but for a specialist audience, that depth is exactly what makes it valuable.

   Helpful? 0 0
   Dr. Melissa Grant

   Rated 5 out of 5

   This course does an excellent job showing how neuro-oncology has become more molecular, multidisciplinary, and patient-specific. The lectures on WHO c...More

   This course does an excellent job showing how neuro-oncology has become more molecular, multidisciplinary, and patient-specific. The lectures on WHO classification and biomarkers were especially useful because they clarify why accurate diagnosis is now inseparable from treatment planning. I also appreciated the attention given to long-term complications and survivorship, since these issues matter greatly for patients and families. The course is information-heavy, so it requires focus, but it rewards careful viewing. I would recommend it to neurologists, oncologists, neurosurgeons, radiation oncologists, and advanced trainees who want an updated overview.

   Helpful? 0 0
   Dr. Andrew Collins

   Rated 5 out of 5

   I found this course useful because it brings together many topics that are usually scattered across different meetings or journal reviews. The agenda ...More

   I found this course useful because it brings together many topics that are usually scattered across different meetings or journal reviews. The agenda includes pediatric tumors, adult primary brain tumors, metastases, neurogenetic syndromes, neuropathology, neuroradiology, and cancer therapy complications. That breadth makes it helpful for clinicians who participate in tumor boards or coordinate care across specialties. The recorded format is convenient, especially for revisiting complex lectures. A few sessions could benefit from more case summaries, but the tumor board components partially address that. Overall, it is a strong and practical update.

   Helpful? 0 0
   Dr. Priya Nair

   Rated 5 out of 5

   The course is comprehensive and very relevant for clinicians caring for patients with brain and nervous system tumors. I especially valued the pediatr...More

   The course is comprehensive and very relevant for clinicians caring for patients with brain and nervous system tumors. I especially valued the pediatric lectures because they explained different tumor entities in a focused and practical way. The adult section is also strong, particularly the sessions on glioma classification, IDH status, and experimental therapies. The faculty expertise is evident throughout the material. Some presentations are very detailed, which may feel challenging for non-specialists, but the benefit is that the course does not oversimplify complex topics. It is a reliable update for serious clinical learning.

   Helpful? 0 0
   Dr. Christopher Allen

   Rated 5 out of 5

   This is a well-built course for reviewing both pediatric and adult neuro-oncology. The lectures are concise but rich in content, and the agenda covers...More

   This is a well-built course for reviewing both pediatric and adult neuro-oncology. The lectures are concise but rich in content, and the agenda covers many areas that are important in real practice. I appreciated the attention given to imaging, pathology, radiation advances, surgical developments, and experimental therapies, because treatment decisions are rarely made from one perspective alone. The third day on complications of cancer is a major strength. It helped reinforce how neuro-oncology is not only about tumors, but also about managing the neurological consequences of cancer and its treatments.

   Helpful? 0 0
   Dr. Rachel Thompson

   Rated 5 out of 5

   The Harvard Annual Update in Neuro-Oncology 2025 provides an organized and thoughtful review of a fast-moving field. I found the adult glioma sessions...More

   The Harvard Annual Update in Neuro-Oncology 2025 provides an organized and thoughtful review of a fast-moving field. I found the adult glioma sessions particularly helpful because they connect molecular diagnosis with clinical decision-making. The section on neurological complications of cancer is also very relevant, especially as immunotherapies and newer systemic treatments become more common. The course is best suited to clinicians and advanced trainees, not casual learners, because the language and concepts assume some medical background. For its intended audience, however, it is detailed, relevant, and worth studying carefully.

   Helpful? 0 0
   Dr. Daniel Morgan

   Rated 5 out of 5

   I was impressed by the scope of the course. It covers both common and uncommon neuro-oncology topics, including gliomas, embryonal tumors, ependymomas...More

   I was impressed by the scope of the course. It covers both common and uncommon neuro-oncology topics, including gliomas, embryonal tumors, ependymomas, meningiomas, CNS lymphoma, pituitary tumors, brain metastases, and paraneoplastic syndromes. The lectures feel current and clinically grounded, with enough scientific detail to be useful for specialists. The discussions around WHO classification and molecular biomarkers were among the most important parts. I would have liked more downloadable quick-reference tables, but the video content itself is strong. This is a practical update for anyone working in a multidisciplinary cancer environment.

   Helpful? 0 0
   Dr. Hannah Lewis

   Rated 5 out of 5

   This course is a strong fit for clinicians who need a structured review of neuro-oncology in 2025. I appreciated the combination of pathology, radiolo...More

   This course is a strong fit for clinicians who need a structured review of neuro-oncology in 2025. I appreciated the combination of pathology, radiology, treatment strategy, and practical complication management. The tumor board sessions add an important clinical dimension by showing how expert faculty think through real scenarios. The pediatric section is detailed and useful, particularly for rare tumors and neurogenetic syndromes. Some lectures move quickly, especially when covering molecular classification, but the recorded format helps a lot. Overall, it is a high-quality educational resource for professionals involved in CNS tumor care.

   Helpful? 0 0
   Dr. Jonathan Price

   Rated 5 out of 5

   The course delivers a solid overview of modern CNS and PNS tumor management. I liked the way the three-day agenda is organized, starting with pediatri...More

   The course delivers a solid overview of modern CNS and PNS tumor management. I liked the way the three-day agenda is organized, starting with pediatric neuro-oncology, moving into adult brain tumors, and finishing with neurological complications of cancer. The recorded lectures are useful for reviewing complicated topics at a comfortable pace. The content on brain metastases, leptomeningeal disease, and immunotherapy complications was particularly valuable for my practice. My only reason for giving four stars is that the material is highly dense, so beginners may need additional references. For experienced clinicians, it is an excellent update.

   Helpful? 0 0
   Dr. Laura Bennett

   Rated 5 out of 5

   I found this course very helpful for updating my understanding of current neuro-oncology practice. The strongest feature is the multidisciplinary appr...More

   I found this course very helpful for updating my understanding of current neuro-oncology practice. The strongest feature is the multidisciplinary approach, because it reflects how these patients are actually managed. The sessions on molecular biomarkers and imaging advances were especially relevant, and I appreciated the inclusion of survivorship and late complications. Some sections are quite specialized and may require pausing or reviewing background material, particularly for learners outside neurology or oncology. However, that depth is also what makes the course worthwhile. It is a strong resource for clinicians who want a serious, detailed review.

   Helpful? 0 0
   Dr. James Anderson

   Rated 5 out of 5

   This is one of the more complete neuro-oncology updates I have reviewed. The material is broad enough to cover pediatric CNS tumors, adult gliomas, me...More

   This is one of the more complete neuro-oncology updates I have reviewed. The material is broad enough to cover pediatric CNS tumors, adult gliomas, meningiomas, CNS lymphoma, pituitary tumors, metastases, leptomeningeal disease, and complications of cancer therapy. At the same time, the lectures remain focused and clinically meaningful. The faculty lineup gives the content a high level of authority, especially in areas such as WHO classification, imaging advances, and experimental therapies. For anyone involved in tumor boards or multidisciplinary CNS cancer care, the course provides a strong refresher and several practical takeaways.

   Helpful? 0 0
   Dr. Sarah Mitchell

   Rated 5 out of 5

   What stood out to me was the balance between advanced academic content and real-world clinical relevance. The course does not simply list tumor types;...More

   What stood out to me was the balance between advanced academic content and real-world clinical relevance. The course does not simply list tumor types; it explains why molecular pathology, neuroradiology, surgery, radiation, and medical oncology must be interpreted together. The pediatric neuro-oncology day was particularly strong, especially the sessions on low-grade gliomas, high-grade gliomas, ependymomas, and neurogenetic syndromes. I also liked that metastatic disease and neurological complications of cancer were given a full dedicated day. This makes the course useful for neurologists, oncologists, neurosurgeons, and trainees who want a comprehensive update.

   Helpful? 0 0
   Dr. Michael Reynolds

   Rated 5 out of 5

   The structure of this neuro-oncology update is excellent. It moves from pediatric tumors to adult gliomas and then into neurological complications of ...More

   The structure of this neuro-oncology update is excellent. It moves from pediatric tumors to adult gliomas and then into neurological complications of cancer in a logical progression. I found the lectures on IDH-mutant and IDH-wildtype gliomas especially useful, because they clarify how modern classification directly affects treatment planning and prognosis conversations. The course also does a good job highlighting complications from immunotherapy and long-term survivorship issues, which are often underrepresented in standard oncology training. It is dense, but the recorded format makes it easy to revisit the most important sessions.

   Helpful? 0 0
   Dr. Emily Carter

   Rated 5 out of 5

   This course gives a clear and clinically useful update on neuro-oncology without feeling superficial. I appreciated how the pediatric and adult sectio...More

   This course gives a clear and clinically useful update on neuro-oncology without feeling superficial. I appreciated how the pediatric and adult sections were separated, because each patient population has very different diagnostic and treatment considerations. The strongest parts for me were the WHO classification updates, the molecular biomarker discussions, and the tumor board style sessions. They helped connect pathology, imaging, surgery, radiation, and systemic therapy into one practical framework. For clinicians who already see complex CNS tumor cases, this is a valuable way to refresh knowledge and identify where practice is changing.

   Helpful? 0 0